VBNK vs PRME
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
VBNK · VersaBank$0.00 ▲ 2.23%
PRME · Prime Medicine$3.55 ▼ 7.55%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- VBNK +76.2%
- PRME -6.3%
Head to head
| Metric | VBNK | PRME |
|---|---|---|
| Price | $0.00 | $3.55 |
| Change today | ▲ 2.23% | ▼ 7.55% |
| Market cap | $789.08M | $791.62M |
| Return, 3 months | +5.0% | +9.2% |
| Return, year to date | +36.6% | +2.3% |
| Return, 1 year | +76.5% | -2.2% |
| P/E (TTM) | 33.2 | – |
| P/B | 2.0 | 93.4 |
| P/E percentile vs own 5y | 99th | 29th |
| Dividend yield | 0.29% | – |
| Revenue growth (YoY, latest qtr) | +22.9% | +243.9% |
| Net profit growth (YoY) | +52.8% | +22.8% |
| Gross margin | – | – |
| Operating margin | – | -2,584.2% |
| Net margin | 22.8% | -2,497.6% |
| Return on equity | 6.2% | -207.2% |
| Analyst target vs. price | – | +131.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 35 | 43 |
| 30-day volatility | 48.9% | 140.8% |
| Max drawdown, 1 year | -21.0% | -42.2% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PRME is the largest of the group by market value.
- VBNK has returned the most over the past year.
- PRME is growing revenue fastest.
- VBNK keeps the most profit per dollar of sales.
- VBNK has been the calmest stock over the last 30 days.